

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). *Lancet Oncol* 2015; published online January 29. [http://dx.doi.org/10.1016/S1470-2045\(15\)70004-5](http://dx.doi.org/10.1016/S1470-2045(15)70004-5).

Characteristics of Evaluable Patients (NRG 240)

Characteristics	CIS+PAC		CIS+PAC+BEV		TOP+PAC		TOP+PAC+BEV	
	n=99		n=98		n=95		n=98	
	N	%	N	%	N	%	N	%
Age Group								
<=39	9	9	12	12	11	12	12	12
40-49	34	34	31	32	33	35	23	23
50-59	24	24	29	30	25	26	38	39
60-69	20	20	15	15	21	22	20	20
>=70	12	12	11	11	5	5	5	5
Race								
Asian	3	3	7	7	2	2	5	5
Black	10	10	16	16	11	12	15	15
Other	5	5	3	3	7	7	5	5
White	81	82	72	73	75	79	73	74
Ethnic origin								
Hispanic	15	15	12	12	10	11	10	10
Non-Hispanic	79	80	80	82	82	86	85	87
Other/Unspecified	5	5	6	6	3	3	3	3
Performance Status								
0	61	62	58	59	60	63	58	59
1	38	38	40	41	35	37	40	41
Disease Status								
IV	18	18	17	17	18	19	15	15
Persistent	3	3	14	14	14	15	12	12
Recurrent	78	79	67	68	63	66	71	72
Previous Platinum-containing therapy								
Yes	71	72	73	74	68	72	74	76
No	28	28	25	26	27	28	24	24

Number of QOL assessments completed by treatment groups (NRG 240)

Baseline	# Assessment completed	CIS+PAC	CIS+PAC+BEV	TOP+PAC	TOP+PAC+BEV
No	0	3	3	3	5
	1	3	2	0	0
	2	0	0	2	1
	3	0	0	0	1
	4	1	1	0	1
Yes	1	8	11	11	6
	2	19	15	20	14
	3	20	23	24	23
	4	27	24	15	23
	5	33	36	36	38

Number of patients who completed QOL assessment at 9 months by disease progression status (NRG 240)

Regimens	Disease progression	No.	QOL completed at 9 months	
			No.	%
CIS+PAC	No	34	25	74
	Yes	38	22	58
CIS+PAC+BEV	No	47	31	66
	Yes	28	16	57
TOP+PAC	No	31	19	61
	Yes	32	23	72
TOP+PAC+BEV	No	41	29	71
	Yes	31	22	71